Turtle C J, Hart D N J
Dendritic Cell Laboratory, Mater Medical Research Institute, Level 3, Aubigny Place, Raymond Terrace, South Brisbane, Queensland, 4101, Australia.
Curr Drug Targets. 2004 Jan;5(1):17-39. doi: 10.2174/1389450043490640.
Despite rapid advances in cancer therapeutics, relapsed disease due to failed immunosurveillance remains a major problem in many cancers. Dendritic cells are recognized as key to the induction of immune responses to cancer and intensive study is underway to facilitate their use in cancer immunotherapy. In initial clinical trials, dendritic cell preparations were, with the benefit of hindsight, largely sub-optimal, yet encouraging results have been seen. The challenge now is to expand our knowledge of the interactions between tumors and the immune system, through basic scientific research and coordinated large-scale clinical studies. This review focuses on the anti-tumor immune response, human dendritic cell biology and the results of recent clinical studies of dendritic cell immunotherapy for cancer.
尽管癌症治疗取得了迅速进展，但由于免疫监视失败导致的疾病复发仍是许多癌症中的一个主要问题。树突状细胞被认为是诱导针对癌症的免疫反应的关键，目前正在进行深入研究以促进其在癌症免疫治疗中的应用。在最初的临床试验中，事后看来，树突状细胞制剂在很大程度上并不理想，但也取得了令人鼓舞的结果。现在的挑战是通过基础科学研究和协调的大规模临床研究，扩大我们对肿瘤与免疫系统之间相互作用的认识。本综述重点关注抗肿瘤免疫反应、人类树突状细胞生物学以及树突状细胞免疫治疗癌症的近期临床研究结果。
